All posts by imreal

Cold Fire Firefighting Wetting Agent Supplied by Shield-Safety Is Now Certified Free of Toxic Chemicals by an Accredited Department of Defense Laboratory


Shield-Safety Cold Fire Tactical Extinguisher

Safety at Work Starts With Safety at Home

Shield-Safety’s is proud to announce that Firefreeze Worldwide’s acclaimed Cold Fire fire fighting wetting agent is certified PFAS free as of May 7, 2020. It has always been produced without PFAS chemicals but was recently tested in accordance with EPA 537 and 537.1 regulations. Polyfluoroalkyl and perfluoroalkyl substances (PFAS) including PFOA and PFOS are used worldwide in a variety of industries including firefighting foams. They are man-made chemicals that can accumulate over time causing negative health effects to our bodies, our environment and are non-biodegradable. These chemicals are known carcinogens and the cause of many physical problems in prolonged exposures according to laboratory studies. The effects of these chemicals on the body can cause the kidneys and liver to reach toxicity, weaken the immune system, interrupt natural hormone production and lead to cancer development. The PFOA Stewardship Program was formed by the Environmental Protection Agency to eliminate the use of PFAS and PFOA in manufacturing in the United States. Cold Fire can affirm that it is free of these harmful chemicals, non-toxic and safe for the environment. Consumers and firefighters alike can feel confident in using Cold Fire for emergency situations and fire safety needs.

Cold Fire is a product that can be utilized by a number of vocations and applications needing quick access to a portable fire extinguisher. As a handheld tactical extinguisher it can quickly and effectively extinguish class D and K fires while encapsulating hydrocarbons. It works to remove the fuel source and heat from the fire tetrahedron preventing reignition 21 times faster than water. Cold Fire is also tested in accordance with UL 162 for class A and B fires and NFPA 18 Standards for UL listed wetting agents. Cold Fire can put out fires safer and faster than water causing less water damage to property and less risk to consumers and firefighters. It is completely green and also available in bulk for larger applications.

Shield-Safety has over 35 years of experience as a leader in community, business and industrial first aid and safety training. As an expert in America’s home and workplace safety we understand the need and importance for environmentally safe emergency products. Saving yourself or others from an emergency situation shouldn’t have unforeseen negative effects down the road. Shield-Safety shares the same enthusiasm and commitment to the safety of people and our environment as Firefreeze Worldwide, Inc. and their Cold Fire products.

Resources:

https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-and-polyfluoroalkyl-substances-pfas

Share article on social media or email:

Biotech Startups Tackle the COVID-19 Challenge


News Image

Snuggled into the Catoctin Mountains, Frederick, Maryland, captures travel headlines as a destination for its “hipstoric” character, a blend of picturesque architecture and artful vibes enfolded with rich colonial history and a growing reputation as a foodie haven, but something else is happening here. As the world shudders to a halt, trying to stop the deadly spread of COVID-19 infections as if it were an invasion of invisible zombies, Frederick’s biotech startups rev up for the fight.

The town’s location, home to frontline biomedical research at Fort Detrick and easily accessible to major East Coast cities like DC and Baltimore, make it an enclave for scientific enterprise. The Frederick Innovative Technology Center, Inc., also known as FITCI, presses that advantage. The organization is an incubator and accelerator started with public/private support in 2004, nurturing more than 150 fledgling companies throughout the years. Today, FITCI is recognized as a premier resource for technology and bioscience entrepreneurs because of its in-depth programming, industry-specific mentoring and resource array.

Like businesses across the board, start-ups here are acutely affected by social distancing requirements, especially in active labs, and the need to protect employees while navigating a swiftly changing economy. FITCI’s Strategic Growth and Advisory Board (SGAB), acts as a board of directors for client companies. Successful C-suite executives populate several specialized sessions, readily sharing insight on everything from crafting a corporate culture to hiring a team, through establishing best practices, honing an investors’ pitch or learning when to delegate. The groups’ most pressing issue these days is helping emerging entrepreneurs tame the chaos, turning challenges into opportunities – both to preserve the nascent roots of future industry and economic stability while making a meaningful contribution in the fight against COVID-19.

Here are the companies and their stories: #COVID-19 Startups Tackle COVID-19 – https://www.fitci.org/COVIDPR.html

VIRINTEL, LLC – VirIntel is a diagnostics startup founded in April 2020 in response to the pandemic. The company is developing a serological antibody test for COVID 19 that will tell whether a person was infected with the coronavirus and has gained the immunity as well as will help to evaluate what kind of immunity the person has now. The company hopes that its test will show greater accuracy than current market tests, which often suffer from higher-than-acceptable false negativity/positivity.

VERALOX Therapeutics – VERALOX Therapeutics is a small-molecule biotech company formed in September 2017. The company initially garnered attention for its first product, VLX-1005, a promising rare blood disorder treatment drug for heparin-induced thrombocytopenia and thrombosis (HITT). With the unexpected danger in COVID-19 infections and increased risk of pulmonary embolism (micro clots in the lungs) the VLX-1005 can be used to turn the activation state of the platelets off. This does not kill platelets, but does prevent them from forming clots. Currently, VERALOX is gathering COVID-19 patient blood samples for testing. Once through GLP toxicology testing, the drug poses promising use as an emergency therapy if a second wave of COVID-19 infection occurs.

Integrated BioTherapeutics, Inc. – Integrated BioTherapeutics (IBT) is a biotechnology company focused on discovering novel vaccines and therapeutics for emerging infectious diseases. Their two main pipelines are antiviral (filoviruses) and antibacterial (novel vaccines and therapeutics against bacterial infections). In addition, IBT has a CRO division providing discovery services and reagents for pharma/Biotech and academic institutions. Service including in-vitro screening (in-house models for testing whether the virus can be neutralized) and in-vivo models (allows translation of the in-vitro screening to an in-vivo model). Faced with an 80% dip in demand for research tools for universities and industry, they’ve effectively pivoted to offering services for COVID-19 research.

Velocidy Bio, Inc. – Velocidy Bio delivers solutions that decrease time-to-results for global biological laboratories, often condensing wait time from hours or days into minutes. Along with the company’s Dutch biotech partner, Molecular Biology Systems (MBS), they introduced NEXTGENPCR, a revolutionary new method that decreases testing time for SARS-CoV-2 to eight minutes, compared to current systems that take over an hour. The product has the potential to revolutionize testing capabilities during the pandemic. It could potentially test every employee at nearby Frederick Memorial Hospital every day in about 3 hours. Velocidy Bio is also collaborating with FITCI graduate GM Biosciences on a COVID-19 testing project.

Danuvius Biosciences – Established in 2020 as a spin‐out of Bioworld Consulting Laboratories, Danuvius Biosciences develops monoclonal antibodies for therapies and diagnostic assays for treatment and diagnosis of multi-drug resistant bacterial infections. Because COVID-19 symptoms are very similar to flu, Danuvius Biosciences decided to adapt its rapid (10 minutes) multiplex diagnostic assay to detect and identify the most common infectious agents associated with respiratory infections. This rapid Point of Care multiplex assay will be able to detect and identify the infectious agent in minutes in physician’s office or hospitals, facilitating correct treatment of patients. Validations for the other infectious agents are also in progress.

Hawkeye MedTech – Hawkeye MedTech, Inc. created TotalCare, a unique telemedicine platform that lets patients schedule virtual visits with their own healthcare providers. The company started market validation as the COVID-19 crisis began unfolding. The platform lets patients get the care they need from the comfort of their home or office, while adhering to the highest principals of patient privacy and security.

RebuImmunity, LLC – RebuImmunity, LLC is a small pharmaceutical entity developing recombinant chimeric proteins for clinical drug research and development needs. The company’s patent-pending human-source chimeric protein (BY-001) is a promising novel drug aimed at treating patients with autoimmune diseases. In response COVID-19, RebuImmunity proposed a chimeric protein (RADA2-Fc4) that contains only the certain binding domain of a protein in ACE-2, but does not include catalytic domain of angiotensin II, this structure prevents the protein from interfering with circulating angiotensin II levels. The Fc4 part in this chimeric protein can form a three-part structure, which is necessary for 2019-nCoV binding. Studies show that COVID-19 uses the receptor binding domain (RBD) for its invading cells. In effect, this drug uses existing therapeutic targets as a springboard for the treatment of COVID-19.

GoFightCOVID.com – The Edge graduate Gary Lopez helms Tiny Code, an emergency communication device that facilitates essential communication during natural disasters, but COVID-19 prompted him to start GoFightCovid, a free delivery platform for those who are most at-risk for contracting the devastating virus.

CarrTech, LLC – Sue Carr is a graduate of FITCI’s first intensive accelerator series, The Edge. A former pharmacist with 35+ years’ experience, Carr and her partners created a next-generation filtered needle for safer, easier, quicker drug delivery with less medical waste. According to Carr, it is a much-need update to the current, cumbersome 2-needle system which can result in needle-stick and glass shard injuries.

Poochon Scientific – Poochon Scientific provides mass spectrometry-based protein analysis services and Sanger DNA sequencing services. CEO Jon Hao says he sees a special responsibility to help fight COVID-19. The company helps biomedical research institutions, biotechnology and pharmaceutical companies through DNA sequencing and Proteomics solutions.

Molecular Tools, LLC – Dr. Olena Lar founded Molecular Tools in 2018 with the mission to translate scientific discoveries into easy-to-use standardized tests for biomedical research and clinical diagnostics. Right before the pandemic, Molecular Tools released their first product, an Unconjugated Bilirubin Quantification Kit, designed for easy and direct measurement of unconjugated bilirubin in biological specimens. When the global health emergency put a halt on most research, Dr. Lar joined CianDx- diagnostic lab in Frederick, MD, to support COVID-19 testing.

StepFusion – The Tate Home Assistant is StepFusion’s first product line, now in development. It is a series of everyday items with smart sensors to support dementia care at home, in senior-living communities, and in dedicated nursing facilities. The product can determine how the person is doing or feeling, whether they are showing any COVID-19 symptoms. This information is reported to family or care providers immediately, so they can take the appropriate actions.

Integrated Pharma Services, LLC – Integrated Pharma Services (IPS), is an award-winning Contract Research Organization (CRO) started by Dr. Mina Izadjoo, the company’s president and Chief Science Officer. IPS engages Ph.D. level scientists and skilled technical staff to design, troubleshoot, conduct, analyze, and report scientific data. Recently, IPS received $100K grant from the State of Maryland for manufacturing much-needed surgical masks. IPS tests antiviral properties of new products and devices, including essential personal protective equipment (PPE) and is offering consulting and testing services for COVID diagnostic kits.

RoosterBio, Inc. – RoosterBio has had a steep trajectory from one-man show to international market disruptor. The company remains laser focused on the rapid commercialization of scalable regenerative cures using human mesenchymal stromal/stem cells (hMSC). RoosterBio’s products and services – mesenchymal cells, bioprocess growth and EV collection media – already changed how companies and institutions pro-duce, consume and use living cells, effectively eliminating the bottlenecks in stem cell accessibility. Exciting news, since clinical research suggests that hMSCs might be helpful against the end stage of severe COVID-19, or acute respiratory distress syndrome (ARDS), or to mitigate some of the damaging inflammatory response. Founder Jon A. Rowley, PhD, says that may give patients a fighting chance against severe COVID-19.

READ more details about each of these companies at https://www.fitci.org/COVIDPR.html

SteelBridge Solutions Becomes Sapient Group, Acquires HR Technology Survey


People strategy and workplace technology will be critical to navigating the complex challenges facing HR leaders in this volatile environment. We’re excited to bring the wisdom and expertise of this team to help our clients tackle those problems with confidence.

After 7 years of helping clients achieve dramatic results in HR performance, change management and organizational transformation, SteelBridge Solutions, Inc., is changing its name to Sapient Insights Group and substantially expanding its team and offerings to better serve its clients.

The newly formed research and advisory firm will focus on equipping clients with data and insights to drive enterprise-wide people and financial outcomes across a spectrum of industries, including financial services, energy and utilities, manufacturing, technology, telecom, healthcare, insurance and the public sector.

As part of this shift, Sapient is partnering with Sierra-Cedar to publish its annual HR Technology Survey, which taps user-driven data to help companies make better investments into people, process and technology. This partnership allows them to combine data from 23 years of technology trends from thousands of unique organizations annually and blend it with unparalleled consulting and technology expertise.

“Sapient has the experience, the knowledge and most importantly the data to help companies to navigate these challenges,” said Stacey Harris, chief research officer and managing partner of Sapient. “No other HR Tech Survey has this much depth of information coming straight from users on the ground. We have surveyed more than 18,000 unique organizations covering 290 million employees over the life of the survey. It is truly the voice of the customer.”

Sapient Solutions Group will be led by:

Susan Richards, SPHR, managing partner. Richards has more than 20 years of experience leading HR technology, strategy, organizational effectiveness, change management and transformation engagements. Previously, she has served as CEO of SteelBridge and worked at Wipro Consulting Services, Mercer HR Consulting, Buck Consultants, Deloitte and IBM. She earned an MBA from Virginia Commonwealth University and a BA from Maryville College.

Teri Zipper, chief operating officer. Zipper specializes in helping organizations improve their HR technology strategy, process, change and execution. She previously served as SteelBridge’s COO, and she also worked at Mercer and PeopleFluent. She has a BS in business administration and finance from the University of Louisville. She is also a member of WorldAtWork.

Stacey Harris, chief research officer and managing partner. Harris has been a leading member of the HR practices and technology research community since 2007, producing groundbreaking research on high-impact HR organizations, enterprise HR technology, and key practices across the talent management spectrum. She previously served as vice president of research and analytics for Sierra-Cedar, where she oversaw Sierra-Cedar’s Annual HR Systems Survey and Research. Prior to joining Sierra-Cedar, Harris held executive level research roles with research organizations Bersin & Associates and Brandon Hall Group. Harris has MA and BA degrees from Kent State and Ashland University.

Kim Seals, strategic adviser. Seals has more than 25 years of global experience in human resource consulting, M&A, as well as corporate and leadership roles. She is a founding member and co-chair for the Atlanta chapter of Golden Seeds, where she has been a managing director at Golden Seeds since 2013. In addition to her role with Golden Seeds, she also serves as a General Partner of The JumpFund. Seals previously served as a senior partner with Mercer, responsible for leading their overall go-to-market strategies in the southeast region. She received her BS in Psychology from Louisiana State University.

“People strategy and workplace technology will be critical to navigating the complex challenges facing HR leaders in this volatile environment. We’re excited to bring the wisdom and expertise of this team to help our clients tackle those problems with confidence,” Richards said.

Share article on social media or email:

D’OXYVA® Launches Upgraded Liquid Capsules and Assortment of Active Solutions


News Image

D’OXYVA® is a groundbreaking, completely painless, and noninvasive transdermal delivery system that has been shown to improve health indicators like blood pressure, tissue oxygenation, and wound healing even where standard treatments have failed, evidenced by several clinical trials.

D’OXYVA® is a groundbreaking, completely painless, and noninvasive transdermal delivery system that has been shown to improve health indicators like blood pressure, tissue oxygenation, and wound healing even where standard treatments have failed, evidenced by several clinical trials. Water, which the D’OXYVA® system needs for proper function, is loaded inside a liquid capsule which is then inserted into the D’OXYVA® device. This water is then mixed with the FDA-approved medical grade carbon dioxide from an original D’OXYVA® cartridge, and together produces an active solution of supersaturated carbon dioxide and water vapor, which improves skin microcirculation and blood circulation after dissolving into the skin, thus improving the body’s self-healing functions.

The newly developed, upgraded liquid capsules have a bigger perimeter around the thread where it connects to the D’OXYVA® device. In addition, the “Fill” level marking is now lower, which means the device only requires about half the liquids it used to in order to deliver a higher overall efficiency. Further, this improved liquid capsule can now be prefilled with a variety of active substances like vitamins, caffeine, nutrition supplements, and cannabinoid components like THC or CBD, shown to be effective as pain-relieving substances.

These prefilled “active” liquid capsules can be purchased separately and be adapted to every customer’s needs and wants. The innovative proprietary patented and patent-pending D’OXYVA® technology uses a transdermal delivery route through skin pores instead of through all skin layers, which allows it to achieve a faster and more effective delivery of active components to the underlying blood vessels and the body’s circulatory system. Competing skin delivery technologies try getting the active pharmaceutical ingredients through the skin layers, which often limits the molecular sizes and leads to adverse side effects, such as skin irritation and permanent tissue damage. D’OXYVA® has been reported to have no negative side effects, whereas needle delivery can be painful and cause unwanted side effects.

Furthermore, in comparison with standard of care, the efficiency and cost of D’OXYVA® are unbeatable. D’OXYVA’s pioneering biotechnology provides a simple, effective route of administration that takes just 5 minutes each day. It can be applied while sitting on the sofa watching your favorite show.

For all the above reasons, Circularity Healthcare has received approval from the Western Institutional Review Board to proceed with a Phase 3 clinical study to demonstrate the safety, tolerability, and efficacy of the D’OXYVA® active non-invasive transdermal gas delivery device as an adjunctive treatment in speeding up healing of diabetic foot ulcer (DFU) wounds.

ABOUT CIRCULARITY HEALTHCARE

Circularity Healthcare, LLC, headquartered in Pasadena, California, is an emerging world leader in proprietary circulatory health and noninvasive delivery technologies, committed to helping improve life quality by developing, manufacturing, and marketing medical, pharmaceutical, and consumer health products. Circularity specializes in groundbreaking noninvasive technologies for affordable and portable transdermal delivery systems, and is pursuing regulatory approval worldwide as a way of handling cardiovascular and microcirculatory blood flow issues, as well as immune and autonomic nervous system disorders.

Forward-Looking Information

This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

For more information, please visit http://www.circularityhealthcare.com or

http://www.doxyva.com. Medical experts (Rx only) can visit

http://www.doxyvaforwound.com to send general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info@doxyva.com, info@circularityhealthcare.com or by phone toll free at 1-855-5DOXYVA or at 1-626-244-8090.

Share article on social media or email:

Four Greenberg Traurig Attorneys are Among Nevada’s ‘Legal Elite’


Four attorneys from global law firm Greenberg Traurig, LLP’s Las Vegas office are included in Nevada Business’ 2020 “Legal Elite.” In addition, Shareholder Alayne Opie is listed in Nevada Business’ 2020 “Best Up and Coming.”

According to Nevada Business magazine, thousands of attorney nominations are submitted by their peers each year, and the resulting “Legal Elite” list highlights attorneys who have made significant strides in their respective practices. This year, in addition to Opie, Greenberg Traurig’s Mark Ferrario, Chris Miltenberger, and David Edington are recognized for their accomplishments in the June issue of the magazine.

Ferrario focuses his practice on complex civil litigation and construction law. He is an experienced trial lawyer who has utilized his persuasive skills to obtain favorable results in a wide variety of high-profile matters. He serves as lead counsel in jury trials, bench trials and arbitrations as well as appeals in matters involving construction, securities, contracts, civil rights, election and tort law. Ferrario appears in front of regulatory and legislative bodies on behalf of his clients. He regularly provides counsel to his clients on a variety of risk management topics.

Miltenberger focuses his practice on all types of litigation, with an emphasis on business and commercial disputes. He advises his clients with respect to commercial disputes both prior to the filing of a lawsuit and after the commencement of litigation. Miltenberger has represented a broad range of clients ranging from individual employees and investors to Fortune 500 companies in both state and federal court. As part of his representation, he has managed teams and guided clients through all aspects of litigation, from developing pre-litigation strategies through appeals. Miltenberger’s representations have included advising leaders in the gaming, hospitality and the construction industries in the prosecution and defense of complex, commercial claims.

Opie is a litigator, focusing her practice on business, commercial, gaming, product, employment, and legal malpractice disputes. She has experience in state, federal and multidistrict courts, including single plaintiff actions, class actions, and mass tort actions. Additionally, she has litigated cases involving consumer finance, construction defect, insurance bad faith and medical malpractice.

Edington handles a broad range of commercial real estate, development and finance matters across the country related to all types of real estate classes and has significant experience representing clients in acquisitions, dispositions, and all manner of leasing matters. Edington’s finance practice includes representing borrowers and financial institutions in connection with construction, bridge, and other general secured financings. He has a comprehensive business background, including deep knowledge of common-interest communities and community management, and uses this experience to approach legal issues with a business-oriented perspective and efficiently achieve practical and workable solutions.

About Greenberg Traurig’s Las Vegas Office: Greenberg Traurig’s Las Vegas attorneys counsel clients in appellate, construction, corporate and securities, entertainment, gaming, government law & policy, intellectual property, litigation, and real estate matters.

About Greenberg Traurig, LLP: Greenberg Traurig, LLP (GT) has approximately 2200 attorneys in 41 locations in the United States, Latin America, Europe, Asia, and the Middle East. GT has been recognized for its philanthropic giving, diversity, and innovation, and is consistently among the largest firms in the U.S. on the Law360 400 and among the Top 20 on the Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.

Share article on social media or email:



FastMed Urgent Care Expands COVID-19 Diagnostic & Antibody Testing to All Locations


FastMed Urgent Care, one of the nation’s largest independent urgent care providers, has expanded reliable COVID-19 diagnostic and antibody testing to all of its 100+ clinics across North Carolina, Arizona, and Texas. Both tests are approved under the FDA’s Emergency Use Authorization.

“There are still a lot of unknowns related to COVID-19 and FastMed strives to provide appropriate resources to keep our patients informed, said Dr. Lane Tassin, M.D., FastMed’s co-chief medical officer. “Providers at our clinics are well equipped to guide patients on whether the COVID-19 antibody or diagnostic test is appropriate for them.”

Additionally, FastMed created a free online self-assessment tool on the home page of FastMed.com to help direct patients to the most appropriate site of care, whether that be an in-person clinic visit, virtual visit via telemedicine, or a hospital referral, based on the patient’s answers to questions about their symptoms and medical history.

For patients with COVID-19 symptoms or possible exposure to Coronavirus, a diagnostic test is a good way to find out if you are currently infected and whether further isolation is necessary. A provider evaluation is recommended for patients displaying COVID-19 symptoms.

For the Coronavirus antibody test, patients who have never been symptomatic or have been symptomatic but have recovered from acute illness for two weeks will be evaluated by a FastMed provider to administer the antibody test. This test is not used to diagnose a current COVID-19 infection and a negative result does not rule out an infection. It is important to note that the antibody test does not imply or confirm that you have developed immunity to the COVID-19 virus. The test will only indicate a likelihood that you’ve had exposure to or were infected by the virus in the past.

Patients who are unsure whether their symptoms are related to Coronavirus, or need help to determine which COVID-19 test is right for them, can receive an evaluation from a FastMed provider via telemedicine or through an in-clinic visit.

FastMed also places the highest priority on patient safety. As the only independent urgent care operator in North Carolina, Arizona and Texas that has been awarded The Joint Commission’s Gold Seal of Approval ® for quality, safety and infection control, our patients and communities can rest assured we always put safety first.

To schedule a visit, walk in to your nearest location, or to save time, check-in online at https://fastmed.com/.

###

FastMed Urgent Care owns and operates more than 100 clinics in North Carolina, Arizona and Texas that provide a broad range of acute/episodic and preventive healthcare services 365 days a year. FastMed also provides workers’ compensation and other occupational health services at all its clinics, and family and sports medicine services at select locations. FastMed has successfully treated more than 6 million patients and is the only independent urgent care operator in North Carolina, Arizona and Texas to be awarded The Joint Commission’s Gold Seal of Approval® for quality, safety and infection control in ambulatory healthcare. For more information about locations, services, hours of operation, insurance and prices, visit http://www.fastmed.com.

Share article on social media or email:

Mike Filliben Promoted to Chief Operating Officer of Ranker


“In this expanded role, Mike’s proven leadership skills will be exactly what we need to fuel Ranker and Watchworthy’s continued growth.” -Clark Benson, CEO and founder of Ranker.

Ranker, known as the world’s leading publisher for fan-powered rankings on just about everything, today announced that Mike Filliben has been promoted to Chief Operating Officer. Filliben was the first analytics hire at Ranker in 2014, and most recently served as Senior Vice President of Audience Development and Analytics leading the inception and development of several initiatives that have driven consistent growth and gone on to become core competencies of the company.

With almost 15 years of experience in technology and digital media, Filliben has been fortunate to experience the business from many different angles, holding roles in sales, customer success, product, marketing, operations and analytics.

“Mike is a trusted professional that has been committed to the development of Ranker’s strategic initiatives and business goals for several years,” said Clark Benson, CEO and founder of Ranker. “What we’re seeing in this pandemic is that most digital media publishers are moving to subscription paywalls in a panic, whereas we are fearlessly adapting to the changes with innovations and employee growth. In this expanded role, Mike’s proven leadership skills will be exactly what we need to fuel Ranker and Watchworthy’s continued growth.”

As COO of Ranker, Filliben will oversee publisher and business operations, working with his team to lead the data driven improvement of tactics, processes, and technology in pursuit of consistently superior execution. Those efforts will support the further advancement and evolution of Ranker and Watchworthy, a free personalized TV recommendation app launched in March 2020.

“I’m excited for the opportunity to lead Ranker to the next level of growth and operational inventiveness,” Filliben said. “These are unstable times for the digital media space, but we feel good about the opportunities in front of us and about our ability to execute on them. We’ve got a passionate team that is invested in the future of the company – I’m looking forward to the challenge and what we can accomplish together.”

Prior to his career at Ranker, he was the head of analytics at Military.com, the nation’s largest online Military and Veteran membership organization. He has a B.S. in Business Economics from the University of Arizona and an MBA from the UCLA Anderson School of Management.

More information about Ranker and its leadership can be found here.

About Ranker

Ranker, a Quantcast Top 50 site in the US, attracts more than 20 million monthly unique visitors worldwide and is the leader in fan-powered rankings on just about everything. Whatever the topic – TV, movies, video games, sports, brands, food, lifestyle – Ranker puts the vote into the hands of millions rather than a few critics to answer the questions we are most passionate about. Over 1 billion votes now power Ranker Insights, a treasure trove of psychographic correlation data that delivers personalized consumer recommendations (“if you like X, you’ll also like Y, Z”), and also audience insights to marketers, studios, and platforms seeking a deeper understanding of consumer tastes and preferences. Launched in 2020 and powered by Ranker Insights, Watchworthy is the only statistically relevant, crowd-sourced TV recommendation app available to consumers. Ranker made #187 on Deloitte’s 2019 Technology Fast 500 featuring the fastest growing companies in North America and Built In LA’s Top 50 Mid-Sized Companies To Work For in 2020. Headquartered in Los Angeles, Ranker also has offices in Chicago and NYC.

Share article on social media or email:

Northeast Georgia Urological Associates offers free phone consultation for microscopic vasectomy reversal patients


Free phone consultations are now available to couples desiring a vasectomy reversal. The majority of Dr. John McHugh’s reversal patients are out of town and so a phone consultation is an informative and popular option for the vasectomy reversal couple.

“The patient will usually request a phone consult using our website contact form and I’ll call them for the consult that afternoon,” says Dr. McHugh

Dr. John McHugh has performed hundreds of microscopic vasectomy reversals in his practice owned and accredited urological ambulatory surgery center. Dr. McHugh is one of Georgia’s most experienced urologists performing this technically difficult and time consuming procedure.

Over 400 reversals have been performed in Dr. McHugh’s practice owned and accredited urological ambulatory surgery center.

Patients choosing to travel to Gainesville can rest assured that Dr. McHugh is experienced in microscopic surgery and commonly performs vasectomy reversals.

The pricing is all-inclusive and includes a free phone consultation, overnight accommodations and the confidence in knowing that the general anesthesia is performed by a board certified anesthesiologist.

“Because vasectomy reversals are not covered by insurance, our practice offers a unique niche. The biggest cost component of this procedure for most urologists is the facility fees. Since we own our center we can control those costs and strive to pass those savings along to the patient,” says Dr. McHugh.

“We believe that having 25 years of experience, a record of safety and results, as well as a very competitive all-inclusive price, is why we are Georgia’s leader in microscopic reversals. Our website is very informative and a worthwhile starting point for the couple considering a reversal. The free phone consultation is a very popular resource and I would strongly encourage any interested couple to call or email for a no obligation conversation,” Dr. McHugh added.

Dr. McHugh usually conducts the consultations during his afternoon bike ride using a Bluetooth headset.

“The consult is actually enjoyable and rewarding. The reversal couples tell me call is both informative and convenient and often ask questions together using the phone’s speaker option. And I get the exercise,” McHugh added.

Share article on social media or email:

Talent Development Lacks Strategic Alignment With Organizational Business Goals


News Image

“It’s important to scale back strategically, if necessary, without getting cut off entirely. This helps the organization avoid losing its momentum with developing talent and staying prepared to meet its future needs.” — Holly Bowers, director of training and development at Willmeng Construction.

Talent development functions have room to improve their strategic alignment to business goals, according to a new report by the Association for Talent Development.

Strategic Alignment: Orchestrating Organizational Success, sponsored by MHS Talent Development, shows that only 42 percent of respondents indicated their organization’s talent development and business strategies were aligned to a high or very high extent.

Strategic alignment “starts with defining what counts,” Kimberly Currier, senior director for talent development for Americas at AECOM, said in the report. “We focus on knowing what business strategies are priorities for the year and, from there, understanding what the business needs its people to do to carry out those strategies.”

The head of human resources is most frequently involved in determining talent development strategy, according to 72 percent of the report’s respondents. Next are business unit leaders (60 percent), followed by the head of talent development (57 percent). Thirty-nine percent of organizations involve the chief executive officer in creating the talent development strategy.

Some other key takeaways from the report include:


  • Fifty-six percent of organizations report on talent development’s performance to their boards of directors, and 78 percent do so during meetings of their senior leader or executive teams.
  • Some best practices associated with having high levels of alignment between business and talent development include having talent development programs that reflect official organizational values, using a centralized reporting structure for talent development, having business leaders that vocalize their support for talent development, and enabling talent development leaders to influence business strategy.

Some of the strategic goals of the organization and talent development have been scaled back during the COVID-19 pandemic, but Holly Bowers, director of training and development at Willmeng Construction, noted in the report that doing away with goals or strategies that surround those goals can be detrimental to the organization.

During difficult times for an organization, “It’s important to scale back strategically, if necessary, without getting cut off entirely,” Bowers explained in the report. “This helps the organization avoid losing its momentum with developing talent and staying prepared to meet its future needs. Otherwise, you start over from square one.”

About ATD

The Association for Talent Development (ATD) is the world’s largest professional membership organization supporting those who develop the knowledge and skills of employees, improve performance, and help to achieve results for the organizations they serve. Established in 1943, the association was previously known as the American Society for Training & Development (ASTD).

ATD’s members come from more than 120 countries and work in public and private organizations in every industry sector. ATD supports talent development professionals who gather locally in volunteer-led U.S. chapters and international member networks and with international strategic partners.

For more information, visit td.org.

Share article on social media or email:

CorTechs Labs and HealthLytix Announce Merger to Expand Leadership in Radiology AI Applications to Detect and Quantify Certain Cancers and Neurodegenerative Disease


News Image

“The application of AI tools in advanced quantitative imaging is creating a paradigm shift in regards to how radiologists detect and diagnose cancers and neurological disorders,” said Dr Lawrence N. Tanenbaum, CTO and Director of Advanced Imaging at RadNet

CorTechs Labs Inc., the leading quantitative neuroimaging software company, announced today that it has merged with sister company HealthLytix, a healthcare technology company developing new applications in genetics and medical imaging to improve the screening and early detection of cancer and neurodegenerative disease. Remaining under the name CorTechs Labs, the merged company will leverage the established, global network of institutions that recognize CorTechs Labs as a trusted partner. Integration of HealthLytix technology will enable CorTechs Labs to broaden its focus by now offering quantitative analysis software to improve the screening and early detection of certain cancers. To date, CorTechs Labs partners with close to 1,000 clinical sites in over 35 countries.

“With a better understanding of disease pathology, the need for diagnostic tools that provide fast and accurate diagnostic support are in high demand. By combining the resources of HeathLytix and CorTechs Labs, we will create commercial synergies that accelerate product development, positioning us to best meet these demands,” said Chris Airriess, Ph.D., chief executive officer of CorTechs Labs. “Our mission has – and will continue to be – pushing the envelope in raising the standards of patient care through breakthrough technology that will ultimately improve patients’ lives. We look forward to working with radiologists and oncologists to support their efforts to detect and diagnose cancers early.”

Expediting market access as a result of this merger is especially important given the recent FDA 510(k) clearance of HealthLytix’s RSI-MRI+ for Prostate, a breakthrough imaging software to help improve early detection and diagnosis of prostate, as well as pending approval in brain cancer. This merger further reinforces the company’s mission of providing state-of-the-art technology to better patient care. Improved screening and early detection of certain cancers, such as prostate and soon brain, as well as neurodegenerative diseases, including Alzheimer’s disease, epilepsy, multiple sclerosis and brain trauma are core to the company mission of improving patient outcomes through early radiological detection and tracking.

“The application of AI tools in advanced quantitative imaging is creating a paradigm shift in regards to how radiologists detect and diagnose cancers and neurological disorders,” said Dr Lawrence N. Tanenbaum, CTO and Director of Advanced Imaging at RadNet, the largest US outpatient imaging network, “I have witnessed firsthand how this shift is positively impacting both patients’ lives and physicians’ practices by eliminating subjectivity, improving diagnostic accuracy and reducing the time to diagnosis which is such a critical factor in the patient’s journey.”

CorTechs Labs now has a comprehensive suite of radiology artificial intelligence products:

● NeuroQuant® , the first FDA-cleared software for volumetric MRI processing, provides fast, accurate and proven automated brain image analysis;

● LesionQuant™ provides quick automated lesion segmentation and quantification, specifically FLAIR lesion and brain structure quantification, as well as lesion change visualization;

● RSI-MRI+ for Prostate is FDA-cleared advanced imaging software that improves prostate cancer detection for earlier diagnosis and treatment planning;

● PETQuant™ , providing rapid automated analysis of PET brain studies to quantify subregional tracer binding in native patient brain space, registers to T1 MRI to provide anatomical segmentations, creating an additional tool in the evaluation of neurodegenerative dementias;

● CT CoPilot® is an FDA-cleared quantitative imaging solution that provides consistent views of head CT exams and automated quantitative measurements to improve workflow efficiency, measurement accuracy and clinical confidence.

“The best-in-class technologies resulting from this merger will set a new industry standard for the future of diagnostics and patient care,” said Nathan White, Ph.D., chief technology officer of CorTechs Labs and co-inventor of RSI-MRI+, previously chief executive officer of HealthLytix. “We know the immense value of our technology in catching cancer early. By combining our resources, we can expedite our path to market and deliver this technology to the physicians who will use it, and trust it, to optimize cancer diagnosis and care for patients.”

Early examples of CorTechs Labs’ expanded capabilities were made public in May of 2020 when interpretable AI for chest X-ray and integrated genetic risk analysis were added to the company’s COVID-19 related projects. These were in addition to the company’s flagship brain volumetrics reports, customized to support the study of patients showing neurological effects of the disease, which were made available at no cost to clinicians and researchers working on COVID-19.

CorTechs Labs Inc., an industry leader in radiology AI applications, aims to improve screening and early detection of neurodegenerative diseases and cancers. The company will remain under the leadership of Chris N Airriess, Ph.D., as chief executive officer. Nathan White, Ph.D. will be chief technology officer and the board of directors will largely remain the same, including the healthcare industry leaders that composed each of the previous boards. The company’s primary investor is Dragasac Limited, a subsidiary of leading Malaysian corporation, Genting Berhad, with significant global investment in fostering innovative life science technologies that improve health and patient outcomes. With the continued support of Genting, CorTechs Labs will open its next round of financing in the second half of 2020.

About CorTechs Labs

CorTechs Labs is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so people can enjoy longer, better lives. The company develops and markets breakthrough medical device software solutions that quantify and track neurodegenerative and cancerous conditions. CorTechs Labs’ cutting-edge brain imaging analysis provides neurologists, radiologists, oncologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions as well as prostate cancer. Please visit http://www.cortechslabs.com for further information and follow us on Twitter, LinkedIn and Facebook.

Media Contact:

Travis Foegler

CorTechs Labs

+1 (619) 966-3876

tfoegler@cortechslabs.com

Share article on social media or email: